DAKGESUNDHEIT
A United Kingdom buyer, with 25 published contracts, worth £102.3m, most recently 4 months ago.
Top 5 suppliers won 100% of awarded value — £62.8m of £62.8m across 10 awards.
This contract involves a non-exclusive discount agreement for the pharmaceutical substances Adapalene and Benzoyl Peroxide, classified under ATC code D10AD23. The agreement is established under Section 130a, Paragraph 8 of the German Social Code (SGB V), allowing health insurance funds and pharmaceu
The German Social Code allows health insurance companies and pharmaceutical companies to enter into framework discount agreements for medications covered by statutory health insurance. In accordance with the relevant legal provisions for public procurement, the DAK-Gesundheit will conduct a regular
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Abiraterone (500 mg, 90 tablets) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from December 1, 2025, to November 30, 2027. The process will involve formal procuremen
The German health insurance fund DAK-Gesundheit is seeking suppliers for a non-exclusive discount agreement for the drug Tocilizumab (specifically pre-filled syringes and pens) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from December 1, 2025, to November 30, 2027.
The German health insurance companies and pharmaceutical companies can enter into framework discount agreements for medications covered by statutory health insurance, as permitted by § 130a paragraph 8 of the Social Code Book V. The DAK-Gesundheit will conduct a formal procurement process for the ac
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the medication Clobetasol, specifically in foam form (ATC D07AD01). This agreement is part of a framework established under § 130a Abs. 8 SGB V, which allows health insurance companies and pharmaceutical fir
The German health insurance companies and pharmaceutical companies can enter into framework discount agreements for medications covered by statutory health insurance, as permitted by § 130a paragraph 8 of the Social Code Book V. The DAK-Gesundheit will conduct a formal procurement process for the ac
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Abrocitinib (ATC D11AH08) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will involve formal procurement proced
The DAK-Gesundheit is seeking pharmaceutical companies to enter into a non-exclusive discount agreement for the drug Umeclidinium (ATC R03BB07) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will follow the formal
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the medication containing the active ingredients Tafluprost and Timolol (ATC S01ED70). This agreement is in accordance with § 130a Abs. 8 SGB V, which allows health insurance companies and pharmaceutical com
